Loading...
Loading...
ONCT| Name | Value |
|---|---|
| Revenues | 0.2M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.2M |
| Operating Expense | 12.1M |
| Operating I/L | -12.1M |
| Other Income/Expense | 0.7M |
| Interest Income | 0.7M |
| Pretax | -11.5M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | -11.5M |
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing oncology therapies for cancers with unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody targeting ROR1; ONCT-216, a small molecule inhibiting ETS-family transcription factor oncoproteins; ONCT-808, a CAR-T product targeting ROR1; and ONCT-534, an androgen receptor inhibitor for castration-resistant prostate and other cancers. Oncternal has license agreements with leading research institutions and a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1.
